Inhibition of cardiac HERG potassium channels by antidepressant maprotiline

European Journal of Pharmacology

Volumn 531, Issue 1-3, 2006, Pages 1-8

  Ferrer Villada, Tania ^a   Navarro Polanco, Ricardo A ^a   Rodríguez Menchaca, Aldo A ^a   Benavides Haro, Dora E ^a   Sánchez Chapula, José A ^a  

^a UNIVERSIDAD DE COLIMA   (Mexico)

Author keywords

Acquired long QT syndrome; Arrhythmia; HERG potassium channel; IKr; Maprotiline; QT interval; Rapid delayed rectifier; Torsade de pointes

Indexed keywords

ANTIDEPRESSANT AGENT; MAPROTILINE; POTASSIUM CHANNEL HERG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE DEPOLARIZATION; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; MOLECULAR MECHANICS; NONHUMAN; OOCYTE; POINT MUTATION; PRIORITY JOURNAL; XENOPUS;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BINDING SITES; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; GENE EXPRESSION; HUMANS; MAPROTILINE; MEMBRANE POTENTIALS; OOCYTES; POINT MUTATION; XENOPUS;

EID: 32044433968     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2005.10.036     Document Type: Article

References (39)

1. W. Alvarez Jr., and K.K. Pickworth Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature Pharmacotherapy 23 2003 754 771
2. L. Brachtendorf, A. Jetter, K.T. Beckurts, A.H. Holscher, and U. Fuhr Cytochrome P450 enzymes contributing to demethylation of maprotiline in man Pharmacol. Toxicol. 90 2002 144 149
3. D. Burckhardt, E. Raeder, V. Muller, P. Imhof, and H. Neubauer Cardiovascular effects of tricyclic and tetracyclic antidepressants Jama 239 1978 213 216
4. F. Casazza, F. Fiorista, A. Rustici, and G. Brambilla Torsade de pointes caused by tricyclic antidepressive agents. Description of a clinical case G. Ital. Cardiol. 16 1986 1058 1061
5. + channel blockers J. Med. Chem. 45 2002 3844 3853
6. J. Chen, G. Seebohm, and M.C. Sanguinetti Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels Proc. Natl. Acad. Sci. U. S. A. 99 2002 12461 12466
7. R.A. Curtis, N. Giacona, D. Burrows, J.L. Bauman, and M. Shaffer Fatal maprotiline intoxication Drug Intell. Clin. Pharm. 18 1984 716 720
8. D. Escande Pharmacogenetics of cardiac K(+) channels Eur. J. Pharmacol. 410 2000 281 287
9. D. Fernandez, A. Ghanta, G.W. Kauffman, and M.C. Sanguinetti Physicochemical features of the HERG channel drug binding site J. Biol. Chem. 279 2004 10120 10127
10. O.P. Hamill, A. Marty, E. Neher, B. Sakmann, and F.J. Sigworth Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches Pflugers Arch. 391 1981 85 100
11. H.C. Hermann, L.M. Kaplan, and B.E. Bierer QT prolongation and torsade de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline Am. J. Cardiol. 51 1983 904 906
12. W. Hewer, W. Rost, and W.F. Gattaz Cardiovascular effects of fluvoxamine and maprotiline in depressed patients Eur. Arch. Psychiatry Clin. Neurosci. 246 1995 1 6
13. O. Igawa, H. Kotake, Y. Kurata, M. Saitoh, Y. Fujimoto, J. Hasegawa, and H. Mashiba Electrophysiological effects of maprotiline, a tetracyclic antidepressant agent, on isolated cardiac preparations J. Cardiovasc. Pharmacol. 11 1988 167 173
14. + channels by vesnarinone Mol. Pharmacol. 60 2001 244 253
15. C. Kiesecker, E. Zitron, S. Luck, R. Bloehs, E.P. Scholz, S. Kathofer, D. Thomas, V.A.W. Kreye, H.A. Katus, W. Shoels, C.A. Karle, and J. Kiehn Class Ia antiarrhythmic drug ajmaline blocks HERG potassium channels: mode of action Naunyn-Schmiedeberg's Arch. Pharmacol. 370 2004 423 435
16. J.P. Lees-Miller, Y. Duan, G.Q. Teng, and H.J. Duff Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites Mol. Pharmacol. 57 2000 367 374
17. S. Lentini, M.L. Rao, R. Schroder, B. Luderitz, and G. Bauriedel QT prolongation and torsade de pointes tachycardia during therapy with maprotiline Dtsch. Med. Wochenschr. 126 2001 1396 1400
18. E.L. Michalets, L.K. Smith, and E.D. Van Tassel Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction Ann. Pharmacother. 32 1998 761 765
19. J.T. Milnes, O. Crociani, A. Arcangeli, J.C. Hancox, and H.J. Witchel Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652 Br. J. Pharmacol. 139 2003 887 898
20. J.S. Mitcheson, J. Chen, M. Lin, C. Culberson, and M.C. Sanguinetti A structural basis for drug-induced long QT syndrome Proc. Natl. Acad. Sci. U. S. A. 97 2000 12329 12333
21. J.S. Mitcheson, J. Chen, and M.C. Sanguinetti Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate J. Gen. Physiol. 115 2000 229 240
22. R.A. Pearlstein, R.J. Vaz, J. Kang, X.L. Chen, M. Preobrazhenskaya, A.E. Shechekotikhin, A.M. Korolev, L.N. Lysenkova, O.V. Miroshnikova, J. Hendrix, and D. Rampe Characterization of HERG potassium channel inhibition using CoMSIA 3D QSAR and homology modeling approaches Bioorg. Med. Chem. Lett. 13 2003 1829 1835
23. M. Recanatini, E. Poluzzi, M. Masetti, A. Cavalli, and F. De Ponti QT prolongation through hERG K+ channel blockade: current knowledge and strategies for the early prediction during drug development Med. Res. Rev. 25 2005 133 166
24. W.S. Redfern, L. Carlsson, A.S. Davis, W.G. Lynch, I. MacKenzie, S. Palethorpe, P.K. Siegl, I. Strang, A.T. Sullivan, R. Wallis, A.J. Camm, and T.G. Hammond Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardiovasc. Res. 58 2003 32 45
25. J.G. Reilly, S.A. Ayis, I.N. Ferrier, S.J. Jones, and S.H. Thomas QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients Lancet 355 2000 1048 1052
26. A. Rialan, M. Richard, P. Deutch, and B. Ouattara Torsade de pointes in a patient under long-term maprotiline therapy: apropos of a case Ana. Cardiol. Angeiol. (Paris) 45 1996 123 125
27. J.M. Ridley, J.T. Milnes, H.J. Witchel, and J.C. Hancox High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656 Biochem. Biophys. Res. Commun. 325 2004 883 891
28. + channel block J. Biol. Chem. 277 2002 23587 23595
29. J.A. Sanchez-Chapula, T. Ferrer, R.A. Navarro-Polanco, and M.C. Sanguinetti Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain Mol. Pharmacol. 63 2003 1051 1058
30. M.C. Sanguinetti, and Q.P. Xu Mutations of the S4-S5 linker alter activation properties of HERG potassium channels expressed in Xenopus oocytes J. Physiol. 514 1999 667 675
31. Kr potassium channel Cell 81 1995 299 307
32. A.C. Sims Comparison of the efficacy of sustained-release amitriptyline with maprotiline in the treatment of depressive illness Curr. Med. Res. Opin. 6 1980 534 539
33. W. Stühmer Electrophysiological recording from Xenopus oocytes B. Rudy L.E. Iverson Methods in Enzymology, Ion Channels 1992 Academic Press, Inc. San Diego, CA 319 339
34. M. Trudeau, J.W. Warmke, B. Ganetzky, and G.A. Robertson HERG, a human inward rectifier in the voltage-gated potassium channel family Science 269 1995 92 95
35. W.V. Vieweg, and M.A. Wood Tricyclic antidepressants, QT interval prolongation, and torsade de pointes Psychosomatics 45 2004 371 375
36. H.J. Witchel, J.T. Milnes, J. Mitcheson, and J. Hancox Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes J. Pharmacol. Toxicol. Methods 48 2002 65 80
37. H.J. Witchel, J.C. Hancox, and D.J. Nutt Psychotropic drugs, cardiac arrhythmia, and sudden death J. Clin. Psychopharmacol. 23 2003 58 77
38. H.J. Witchel, C.E. Dempsey, R.B. Sessions, M. Perry, J.T. Milnes, J.C. Hancox, and J.S. Mitcheson The low potency, voltage-dependent HERG blocker propafenone-molecular determinants and drug trapping Mol. Pharmacol. 66 2004 1201 1212
39. E. Zitron, C. Kiesecker, E. Scholz, S. Luck, R. Bloehs, S. Kathofer, D. Thomas, J. Kiehn, V.A. Kreye, H.A. Katus, W. Schoels, and C.A. Karle Inhibition of cardiac HERG potassium channels by the atypical antidepressant trazodone Naunyn Schmiedeberg's Arch. Pharmacol. 370 2004 146 156